Company / FCF Margin
Sunshine Biopharma Inc. FCF Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-40.7%
FY2025
5-year range
-922.1% / -36.8%
FY2021-FY2025
Trend
-10.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -125.2% to -40.7% over the past 2 years.
Based on SEC 10-K filings.
-40.7% in FY2025 with a 5-year CAGR of +2310.8%.
Improved from -125.2% to -40.7% over the past 2 years.
FCF Margin over time
Growth rates
- 3-Year Change
- +760.1pp
- 5-Year Change
- +2310.8pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, fcf margin decreased 10.6% year-over-year.
- Peak fcf margin was recorded in FY2024.
- Lowest fcf margin in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -40.7% | -10.6% |
| FY2024 | -36.8% | +70.6% |
| FY2023 | -125.2% | +84.4% |
| FY2022 | -800.8% | +13.2% |
| FY2021 | -922.1% | +60.8% |
| FY2020 | -2351.5% | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | -51079.5% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026